Coya Therapeutics (NASDAQ:COYA) Issues Earnings Results

Key Points

• Coya Therapeutics reported a quarterly earnings per share (EPS) of ($0.36), missing the consensus estimate of ($0.22) by ($0.14).
• Institutional investors and hedge funds own 39.75% of Coya Therapeutics' stock, indicating significant interest from larger investors.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Coya Therapeutics with a price target of $16.50, despite one analyst issuing a sell rating.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.14), Zacks reports.

Coya Therapeutics Stock Performance

Coya Therapeutics stock traded down $0.06 during trading on Tuesday, hitting $6.09. The company's stock had a trading volume of 32,886 shares, compared to its average volume of 74,266. Coya Therapeutics has a 1-year low of $4.65 and a 1-year high of $10.24. The stock's fifty day moving average is $5.94 and its 200 day moving average is $6.08. The stock has a market capitalization of $101.89 million, a price-to-earnings ratio of -5.86 and a beta of 0.26.

Hedge Funds Weigh In On Coya Therapeutics

A hedge fund recently raised its stake in Coya Therapeutics stock. Jane Street Group LLC boosted its position in Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) by 101.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,137 shares of the company's stock after buying an additional 13,176 shares during the quarter. Jane Street Group LLC owned 0.16% of Coya Therapeutics worth $169,000 at the end of the most recent quarter. Institutional investors and hedge funds own 39.75% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on COYA shares. Wall Street Zen downgraded Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Lake Street Capital assumed coverage on Coya Therapeutics in a research report on Wednesday, July 9th. They set a "buy" rating and a $16.00 price target on the stock. D. Boral Capital reiterated a "buy" rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research note on Thursday, July 24th. HC Wainwright restated a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, June 9th. Finally, Chardan Capital reiterated a "buy" rating and issued a $14.00 price target on shares of Coya Therapeutics in a research report on Tuesday, July 1st. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $16.50.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.